Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

  • days left to enroll
  • participants needed
  • sponsor
    Wake Forest University Health Sciences
Updated on 7 October 2022
multiple myeloma
chemotherapy regimen
peripheral neuropathy


This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of life and amount of chemotherapy that can be given to many cancer patients. Cryocompression is a treatment where a glove and a boot are worn to cool down the skin. This cooling treatment is safe and does not interfere with chemotherapy treatment. Daily cryocompression therapy may reduce neuropathy caused by bortezomib chemotherapy.



I. To assess the feasibility of daily cryocompression therapy in multiple myeloma patients with bortezomib-induced peripheral neuropathy (BIPN).


I. To examine the change in patient-reported assessment of neuropathy based on the sensory, motor and autonomic neuropathy scores on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Cancer-Induced Peripheral Neuropathy (CIPN20) (patient-reported outcome [PRO]) from baseline to 4 and 8 weeks after the start of cryocompression therapy.

II. To examine the change in physician graded assessment of peripheral neuropathy by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 criteria from baseline to 4 and 8 weeks after the start of cryocompression therapy.

III. To assess the effect on sensory and motor nerve function via nerve conduction study (NCS) (e.g. conduction velocity, latency, and amplitude) and neuro-ultrasound after 8 weeks of daily cryocompression therapy.


I. To explore the effect of 8 weeks of cryocompression on changes in digital artery perfusion as measured by ultrasound (US).

II. To examine the associations among the peripheral nerve assessment measures (nerve conduction and peripheral nerve US) with the patient reported outcomes (EORTC QLQ-CIPN20, PRO-CTCAE) at baseline, week 4, week 8, and for the change from baseline to week 8.


Patients undergo home cryocompression therapy treatments on their non-dominant hand and foot over 30 minutes daily for 8 weeks.

After completion of cryocompression therapy, patients are followed up at 30 days.

Condition Chemotherapy-induced Peripheral Neuropathy, Plasma Cell Myeloma
Treatment VascuTherm5 vascular compression device
Clinical Study IdentifierNCT03870451
SponsorWake Forest University Health Sciences
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Patients must have histologically or cytologically confirmed multiple myeloma (any International Staging System [ISS] stage)
Clinical symptoms of bortezomib-induced peripheral neuropathy as measured by the NCI-CTCAE
Cohort 1: Patients with clinically documented CTCAE grade greater than or equal 2
Cohort 2: Patients with clinically documented CTCAE grade 1-2 neuropathy
• Currently or previously received bortezomib-containing regimen
Cohort 1: Patients who have previously received a bortezomib-containing regimen and have
clinically documented neuropathy that is attributed to the bortezomib containing regimen
Cohort 2: Patients who are currently receiving a bortezomib-containing regimen and have
clinically documented neuropathy that is attributed to the bortezomib containing regimen
Eastern Cooperative Oncology Group (ECOG) =< 4
Age must be greater than or equal to 18 years
Ability to understand and the willingness to sign an Institutional Review Board
(IRB)-approved informed consent document
Life expectancy >= 6 months

Exclusion Criteria

Self-reported or documented history of pre-existing peripheral neuropathy prior to
initiation of bortezomib therapy
Other explanatory etiology for neuropathy
Presumptive evidence of congestive heart failure
Current deep vein thrombosis or pulmonary embolism (diagnosed within the past 6
Current pulmonary edema
Unable to provide accurate medical history
Pregnant women are excluded from this study because they will not be receiving myeloma
standard of care (SOC) therapy or bortezomib-based therapy per inclusion criteria
Current or previously documented inflammatory phlebitis; thrombophlebitis
decompensated cardiac insufficiency; arterial dysregulation; erysipelas; carcinoma or
carcinoma metastasis in the affected extremity; decompensated hypotonia; venous or
arterial occlusive disease; or Raynaud's disease
Current monoclonal gammopathy of undetermined significance (MGUS), Waldenstroms
macroglobulinemia, or Castleman disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note